In a breakthrough development, a biochemistry research scholar at the Miller School of Medicine, University of Miami has discovered drug delivery system using nanoparticles can reduce HIV/AIDS viral load in the brain that can contribute to neurological problems.
Whilst managing of HIV as a chronic condition is possible, current drugs used cannot cross the barrier between blood and brain. Therefore, the ability of nanoparticles to transfer antiretroviral drugs to the brain is a significant discovery. This could potentially improve the treatment of brain cancers and other diseases.
Meanwhile, in the past decade, the researcher has been involved in the study of polymer chain nanoparticles as a medium for intracellular drug delivery. The latest finding is published in ACS Nano- the journal of American Chemical Society.
Elaborately, for the study, using an experimental model, the use of biodegradable brain-targeted polymeric nanoparticles to lower AIDS/HIV viral burden accomplished. In addition, the model also included anti-inflammatory and antioxidant neuroprotectants to address inflammation in the brain cells and stress.
Using this model, nanoparticle drug transmission provides a new strategy for the treatment of HIV-related neurocognitive disorders, including dementia. The transmission of nanoparticle drug delivery can be amplified by recreational drug use for HIV-positive people, added the researcher.
From here, in the future, this therapeutic approach that is demonstrated in the laboratory has sizeable potential to improve the treatment of a wide spectrum of diseases.